Search Results
Sep 25, 2025, 08:00 ET Mayer Brown again named "Americas Law Firm of the Year - Overall" and "US Law Firm of the Year" at GlobalCapital's Americas Derivatives Awards
jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC ("PKWN") is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. More information about
More news about: Mayer Brown
Sep 25, 2025, 08:00 ET CODiE Awards Announce 2025 Finalists Recognizing the Most Innovative Products in Technology
Program, Robo WunderkindMobyMax, MobyMaxInStage, InStageBest English Language Arts Instructional Solution for Grades PK - 8 IXL Language Arts, IXL LearningLenses on Literature, Carnegie LearningMobyMax, MobyMaxNewsela
More news about: CODiE Awards
Sep 25, 2025, 06:30 ET AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
EMA and Swissmedic. The Phase 2 study completed by AL-S Pharma evaluated the safety, tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and patients with mutations in the SOD1 gene. About AL-S Pharma AGAL-S Pharma is a Swiss-based
More news about: AL-S Pharma AG
Sep 24, 2025, 20:53 ET Beard Papa's World-Famous Cream Puff Chain Opens New Location in San Diego October 4th, 2025!
beardpapas.com/san-diego-grand-openingFree Limited Edition Mashle: Magic and Muscles surprise gift for the first 100 customers Saturday and Sunday that purchase a Papa's 6pk of puffsExclusive Beard Papa's swag and discounts as part of the Grand Opening.Guests can also enter
More news about: Beard Papa's
Sep 24, 2025, 10:13 ET G-SHOCK UNVEILS THE PINK RIBBON MODEL GMAS145PK-4A
of the GMAS145PK-4A ties back to G-SHOCK's mission: merging ultimate toughness with a deeper social purpose. With its compact case and versatile styling, the model offers everyday wearability while serving as a constant reminder of the power of community and hope. The GMAS145PK-4A is equipped
More news about: Casio America, Inc.
Sep 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: Pomerantz LLP
Sep 22, 2025, 14:34 ET Cornea and Refractive Surgeon Dr. Talia Shoshany Joins OCLI Vision in Connecticut
multifocal, and light-adjustable lenses)Laser vision correction (LASIK, PRK)Corneal transplantation (DSAEK, DMEK, and PK)Keratoconus management, including cross-linking and topography-guided PRKDry eye treatments using the latest technologies
More news about: Spectrum Vision Partners
Sep 18, 2025, 11:57 ET Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransformer® Manufacturing Capabilities
ingredients (APIs), unlocking the potential to deliver poorly soluble drugs across a range of routes of administration. Interim blinded pharmacokinetic (PK) data from single ascending doses of NT-301 powder nasal spray from 1-3 mg demonstrated dose-proportional exposure and rapid absorption (Tmax ~20 minutes)
More news about: Mikart, LLC
Sep 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: Pomerantz LLP
Sep 18, 2025, 05:49 ET AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: The Schall Law Firm
Sep 17, 2025, 08:00 ET Mayer Brown again named "Best Law Firm" at StructuredRetailProducts' SRP Americas Awards
jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC ("PKWN") is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. More information about
More news about: Rubenstein Communications
Sep 16, 2025, 19:30 ET Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
29. 20 mg and 40 mg ASC30 demonstrated superior oral PK profile at steady state. Higher area under the curve (AUC) positively correlated with greater body weight reduction. Table 1 summarizes the PK profile of ASC30. Table 1. PK profile of ASC30
More news about: Ascletis Pharma Inc.
Sep 16, 2025, 07:00 ET AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
Amsterdam, in a poster entitled, "Results from a phase 1, randomized, double-blind, single and multiple ascending oral dose study characterizing the PK, safety, and target engagement of the Rho kinase 1 and 2 inhibitor ROC-101 in healthy volunteers." AllRock was founded by JucaBio, a privately
More news about: AllRock Bio
Sep 16, 2025, 00:30 ET Precision Biometric Launches India's First 'Make in India' DSC Tokens Featuring FIPS 140-3 Certified Secure Elements
India' Digital Signature Certificate (DSC) tokens built on FIPS 140-3 certified secure elements. The new InnaITKey PK32XX USB DSC Token and InnaITKey PK33XX NFC Tap-and-Sign DSC Smart Card set a new benchmark for secure digital transactions, fully meeting the Controller of Certifying
More news about: Precision Biometric India Pvt. Ltd.
Sep 15, 2025, 08:00 ET Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
cancer. The Phase II part plans to enroll approximately 84 subjects. Its primary objective is to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of UTD2 under different dosing regimens in the target patient population and to recommend a dose for Phase III. The Phase III part plans
More news about: Biostar Pharma, Inc.